Association of miR-502-binding site single nucleotide polymorphism in the 3′-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 2, 2014, Pages 149-154

  Yang, Shaodi ^a   Guo, Haiyan ^b   Wei, Benjie ^a   Zhu, Shengcui ^a   Cai, Yanlin ^c   Jiang, Pei ^a   Tang, Jianxin ^a  

^a HUNAN UNIVERSITY OF TECHNOLOGY   (China)

^b XI AN NO 4 HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

non small cell lung cancer; polymorphism; SET8; tp53

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; MICRORNA; MIRN502 MICRORNA, HUMAN; PROTEIN P53; SETD8 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; ASIAN; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; NON-SMALL CELL LUNG CANCER; POLYMORPHISM; RISK; SET8; SINGLE NUCLEOTIDE POLYMORPHISM; TP53;

NON-SMALL CELL LUNG CANCER; POLYMORPHISM; SET8; TP53;

3' UNTRANSLATED REGIONS; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893252227     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt138     Document Type: Article

References (25)

1. Marshall AL and Christiani DC. Genetic susceptibility to lung cancer-light at the end of the tunnel Carcinogenesis 2013, 34: 487-502.
2. Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K and Li N, et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteom 2011, 11: M111.008821.
3. Aranda MDB, Diez RA, Chavez JG, Bermejo RT and Castillo IM. DGI-006 survival study of patients with non-small cell lung cancer treated with Erlotinib. Eur J Hosp Pharm 2013, 20: 120.
4. Beck DB, Oda H, Shen SS and Reinberg D. PR-Set7 and H4K20me1: At the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev 2012, 26: 325-337.
5. Qin Y, Ouyang H, Liu J and Xie Y. Proteome identification of proteins interacting with histone methyltransferase SET8. Acta Biochim Biophys Sin 2013, 45: 303-308.
6. Jøgensen S, Eskildsen M, Fugger K, Hansen L, Larsen MSY, Kousholt AN and Syljuasen RG, et al. SET8 is degraded via PCNA-coupled CRL4 (CDT2) ubiquitylation in S phase and after UV irradiation. J Cell Biol 2011, 192: 43-54.
7. Kim T, Lee SY, Rho JH, Jeong NY, Soung YH, Jo WS and Kang D, et al. Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Mol Cancer Res 2009, 7: 1645-1654.
8. Tardat M, Murr R, Herceg Z, Sardet C and Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol 2007, 179: 1413-1426.
9. Chen K, Song F, Calin GA, Wei Q, Hao X and Zhang W. Polymorphisms in microRNA targets: A gold mine for molecular epidemiology. Carcinogenesis 2008, 29: 1306-1311.
10. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M and Wojcik SE, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010, 70: 2789-2798.
11. Yoon K, Yoon H, Park S, Jang H, Zo JI, Lee H and Lee JS. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small lung cancer. J Thorac Cardiovasc Surg 2012, 144: 794-807.
12. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L and Calin GA, et al. An miR-502-binding site single-nucleotide polymorphism in the 30-Untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 2009, 15: 6292-6300.
13. Guo Z, Wu C, Wang X, Wang C, Zhang R and Shan B. A polymorphism at the miR-502 binding site in the 30-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer 2012, 131: 1318-1322.
14. Wang C, Guo Z, Li Y and Kang S. A polymorphism at the miR-502 binding site in the 30 untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. Cancer Genet 2012, 205: 373-376.
15. Ding C, Li R, Peng J, Li S and Guo Z. A polymorphism at the miR-502 binding site in the 30untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer. Exp Ther Med 2012, 3: 689-692.
16. Papadakis ED, Soulitzis N and Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: The Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 2002, 87: 1013-1018.
17. Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R and Murthy NS, et al. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 2005, 128: 3999-4007.
18. Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ and Kim YC, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer 2011, 73: 264-267.
19. Li J, Shao G, Liu L and Zheng Y. Association of polymorphism of codon 72 in p53 gene with susceptibility and radiosensitivity of non-small cell lung cancer in Chinese population. Zhongguo Fei Ai Za Zhi 2006, 9: 173-176.
20. Hu Y, McDermott MP and Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutation in non-small cell lung cancer. Clin Cancer Res 2005, 11: 2502.
21. Jiang P, Liu J, Li W, Zeng X and Tang J. Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. Acta Biochim Biophys Sin 2010, 42: 671-676.
22. Li Z, Nie F, Wang S and Li L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci USA 2011, 108: 3116-3123.
23. Jøgensen S, Elvers I, Trelle MB, Menzel T, Eskildsen M, Jensen ON and Helleday T, et al. The histone methyltransferase SET8 is required for S-phase Progression. J Cell Biol 2007, 179: 1337-1345.
24. Wu S, Wang W, Kong X, Congdon LM, Yokomori K, Kirschner MW and Rice JC. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dec 2010, 24: 2531-2542.
25. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW and Dutta S, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 2007, 27: 636-646.